Differentiation of Human Pluripotent Stem Cells to Immune Cells for Cell Therapy Development
In this webinar, Diana Golubeva, Scientist in the Immunology group at º£½ÇÆƽâ°æ Technologies, presents a robust, scalable platform for differentiating human pluripotent stem cells (hPSCs) into functional immune cells for allogeneic cell therapy development. By integrating TeSRâ„¢-AOF 3D for xeno-free suspension culture and STEMdiffâ„¢ Hematopoietic-EB reagents, the protocol enables efficient, high-yield generation of CD34⺠hematopoietic stem and progenitor cells (HSPCs). These HSPCs serve as a foundation for downstream differentiation into lymphoid lineages—including natural killer (NK), T, and B cells—using STEMdiffâ„¢ and StemSpanâ„¢ kits, all optimized for feeder-free workflows and scalable bioreactor formats.
As a supporter of, and participant in, ISSCR’s 2025 Annual Meeting, we share with you our presentation at ISSCR 2025. This presentation does not represent an endorsement from or support of the ISSCR.
In this webinar, Diana Golubeva, Scientist in the Immunology group at º£½ÇÆƽâ°æ Technologies, presents a robust, scalable platform for differentiating human pluripotent stem cells (hPSCs) into functional immune cells to support the development of allogeneic cell therapies. By integrating TeSRâ„¢-AOF 3D for xeno-free suspension culture and STEMdiffâ„¢ Hematopoietic-EB reagents, the protocol enables efficient generation of CD34⺠hematopoietic stem and progenitor cells (HSPCs) at high yields. These HSPCs serve as a foundation for downstream differentiation into lymphoid lineages—including natural killer (NK), T, and B cells—using STEMdiffâ„¢ and StemSpanâ„¢ kits, all optimized for feeder-free workflows and scalable bioreactor formats.
Diana highlights how this 3D system supports robust and reproducible immune cell production, with suspension-derived CD34⺠cells demonstrating strong potential for NK and T cell generation and cytotoxicity against multiple cancer targets. Additionally, the new STEMdiff™ B Cell Kit enables the generation of CD19⺠B cells and antibody-secreting cells (ASCs), creating opportunities for applications in immunotherapy and protein replacement. This end-to-end platform offers researchers a powerful, modular solution for generating clinically relevant immune cells at scale, with key benefits for both discovery and translational workflows.
As a supporter of, and participant in, ISSCR’s 2025 Annual Meeting, we share with you our presentation at ISSCR 2025. This presentation does not represent an endorsement from or support of the ISSCR.
Diana highlights how this 3D system supports robust and reproducible immune cell production, with suspension-derived CD34⺠cells demonstrating strong potential for NK and T cell generation and cytotoxicity against multiple cancer targets. Additionally, the new STEMdiff™ B Cell Kit enables the generation of CD19⺠B cells and antibody-secreting cells (ASCs), creating opportunities for applications in immunotherapy and protein replacement. This end-to-end platform offers researchers a powerful, modular solution for generating clinically relevant immune cells at scale, with key benefits for both discovery and translational workflows.
As a supporter of, and participant in, ISSCR’s 2025 Annual Meeting, we share with you our presentation at ISSCR 2025. This presentation does not represent an endorsement from or support of the ISSCR.
Publish Date:
August 04, 2025
Request Pricing
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to º£½ÇÆƽâ°æ Technologies Canada Inc. and its subsidiaries and affiliates (“º£½ÇÆƽâ°æâ€) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
Related Multimedia
-
Robust Workflows for the Expansion of PSCs in 3D Suspension Culture
Publish Date: July 29, 2022 -
Quality Control Guidelines for Clinical-Grade Human Induced Pluripotent Stem Cell Lines
Publish Date: June 09, 2020 -
Accelerating T Cell Therapy Research
Publish Date: October 29, 2021
Explore Our Products
-
Animal origin-free suspension culture medium for human ES and iPS cells -
Compact bioreactor with single-use vessels for high-throughput, 3D suspension culture of hPSCs and other cell types -
For differentiation of human ES or iPS cells into hematopoietic progenitor cells
